abstract |
The use of a combination of: (1) at least one sterols absorption inhibitor or at least one 5alpha-stanol absorption inhibitor and (2) at least one cholesterol biosynthesis inhibitor, for manufacturing of a medicament for the treatment or prevention of vascular inflammation in a subject that has a blood level of c-reactive protein greater than 0.4 mg / dL. |